Selected Conference Presentations
63rd Annual American Society of Hematology (ASH) Meeting and Exposition: December 11 – 14, 2021
* Indicates ASH Abstract Achievement Award
- Pharmacogenomics of Fludarabine in Pediatric HCT Recipients: Preliminary Results *
- Unraveling Subcellular Localization of CD33 Splicing Polymorphism Variant
- The rs35112940 CD33 Polymorphism Reduces CD33 Internalization and Efficacy of CD33-Directed Gemtuzumab Ozogamicin
- Pharmacogenomics to Predict Mucositis in Acute Myeloid Leukemia
- Pharmacogenomic Single Nucleotide Polymorphism (SNP) Variants As Predictors of Toxicity Phenotypes in the Treatment of Acute Childhood Leukemia
- Impact of SAMHD1 Pharmacogenetics on Clinical Outcome in Pediatric AML *
- A Polygenic DNA Damage Repair Pharmacogenomics (DDR_PGx8) Score Predicts GO Response in AML *
American Society for Clinical Pharmacology & Therapeutics Annual Meeting: March 16 – 18, 2022
*Indicates Presidential Trainee Award; **Presidential Trainee Award and David J. Goldstein Trainee Award
- Pharmacogenomic Single Nucleotide Polymorphism (SNP) Scores as a Tool to Predict Toxicity Phenotypes in Treatment of Acute Childhood Leukemia (ALL) **
- A Polygenic DNA Damage Repair Pharmacogenomics (DDR_PGX) Score Predicts Response to Gemtuzumab Ozogamicin in Pediatric AML Patients *
American Association for Cancer Research (AACR) Annual Meeting: April 9 – 14, 2021
- Leukemic cell proteomic profiling in pediatric AML – Abstract No. 2535